These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 21120580)
21. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Van Cutsem E; Rivera F; Berry S; Kretzschmar A; Michael M; DiBartolomeo M; Mazier MA; Canon JL; Georgoulias V; Peeters M; Bridgewater J; Cunningham D; Ann Oncol; 2009 Nov; 20(11):1842-7. PubMed ID: 19406901 [TBL] [Abstract][Full Text] [Related]
22. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Lonardi S; Sobrero A; Rosati G; Di Bartolomeo M; Ronzoni M; Aprile G; Massida B; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Barni S; Zagonel V; Maiello E; Rulli E; Labianca R; Ann Oncol; 2016 Nov; 27(11):2074-2081. PubMed ID: 27573560 [TBL] [Abstract][Full Text] [Related]
23. Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases. Guan M; Chen SC; Ying HY; Zhao L; Li XY; Zhou JF; Shao YJ; Yang XD; Lin Y; Ning XH; Bai CM Chin Med J (Engl); 2012 Oct; 125(20):3640-5. PubMed ID: 23075717 [TBL] [Abstract][Full Text] [Related]
24. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group. Hong YS; Lee SS; Kim KP; Lee JL; Kang YK; Shin SJ; Ahn JB; Jung KH; Im SA; Kim TY; Kim JH; Park YS; Kim TW Am J Clin Oncol; 2014 Feb; 37(1):19-23. PubMed ID: 23111359 [TBL] [Abstract][Full Text] [Related]
25. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Messersmith WA; Jimeno A; Jacene H; Zhao M; Kulesza P; Laheru DA; Kahn Y; Spira A; Dancey J; Iacobuzio-Donahue C; Donehower RC; Carducci M; Rudek MA; Hidalgo M Clin Colorectal Cancer; 2010 Dec; 9(5):297-304. PubMed ID: 21208844 [TBL] [Abstract][Full Text] [Related]
26. XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. Berk V; Ozdemir N; Ozkan M; Aksoy S; Turan N; Inal A; Balakan O; Yasar N; Unal OU; Benekli M; Durnali A; Colak D; Sonmez OU Hepatogastroenterology; 2012; 59(120):2635-9. PubMed ID: 22534542 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604 [TBL] [Abstract][Full Text] [Related]
28. A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients. Nishina T; Takano Y; Denda T; Yasui H; Takeda K; Ura T; Esaki T; Okuyama Y; Kondo K; Takahashi Y; Sugiyama Y; Muro K Jpn J Clin Oncol; 2013 Nov; 43(11):1080-6. PubMed ID: 23999770 [TBL] [Abstract][Full Text] [Related]
29. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E; Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089 [TBL] [Abstract][Full Text] [Related]
30. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A; Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906 [TBL] [Abstract][Full Text] [Related]
31. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. Emmanouilides C; Sfakiotaki G; Androulakis N; Kalbakis K; Christophylakis C; Kalykaki A; Vamvakas L; Kotsakis A; Agelaki S; Diamandidou E; Touroutoglou N; Chatzidakis A; Georgoulias V; Mavroudis D; Souglakos J BMC Cancer; 2007 May; 7():91. PubMed ID: 17537235 [TBL] [Abstract][Full Text] [Related]
32. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685 [TBL] [Abstract][Full Text] [Related]
33. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C; Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083 [TBL] [Abstract][Full Text] [Related]
34. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. Dotan E; Meropol NJ; Burtness B; Denlinger CS; Lee J; Mintzer D; Zhu F; Ruth K; Tuttle H; Sylvester J; Cohen SJ J Gastrointest Cancer; 2012 Dec; 43(4):562-9. PubMed ID: 22294255 [TBL] [Abstract][Full Text] [Related]
35. Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). Maiello E; Di Maggio G; Cordio S; Cinieri S; Giuliani F; Pisconti S; Rinaldi A; Febbraro A; Latiano TP; Aieta M; Rossi A; Rizzi D; Di Maio M; Colucci G; Bordonaro R Clin Colorectal Cancer; 2020 Jun; 19(2):109-115. PubMed ID: 32089455 [TBL] [Abstract][Full Text] [Related]
36. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503 [TBL] [Abstract][Full Text] [Related]
37. Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer. Vedat Bayoglu I; Yildiz I; Varol U; Cokmert S; Kucukzeybek Y; Alacacioglu A; Demir L; Dirican A; Akyol M; Yildiz Y; Oktay Tarhan M J BUON; 2015; 20(2):460-7. PubMed ID: 26011336 [TBL] [Abstract][Full Text] [Related]
38. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064 [TBL] [Abstract][Full Text] [Related]
39. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038 [TBL] [Abstract][Full Text] [Related]
40. Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. Fuse N; Doi T; Ohtsu A; Takeuchi S; Kojima T; Taku K; Tahara M; Muto M; Asaka M; Yoshida S Jpn J Clin Oncol; 2007 Jun; 37(6):434-9. PubMed ID: 17656481 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]